FIT Biotech dives into genes with Avacta
FIT Biotech has initiated a research collaboration with UK-based Avacta Group to develop gene therapies combining the companies’ strengths.
The goal of the co-operation is to assess the suitability of developing gene therapies that use FIT Biotech’s gtGTU platform and Avacta’s Affimer technology. gtGTU vector was developed for gene therapy applications to ensure stable and prolonged expression of DNA-based therapeutics.
According to FIT Biotech, antibodies have been a commercial success. Affimer proteins are a class of non-antibody binding proteins that overcome many of the limitations of antibodies. The aim of the collaboration is to assess whether FIT Biotech’s gtGTU vector technology and Avacta’s Affimer proteins can be utilised to produce a competitive alternative to antibodies.
“Affimer technology offers an exciting opportunity to take targeted therapies to a new level,” says James Kuo, CEO of FIT Biotech. “The high target specificity and small size of Affimer molecules combined with gtGTU’s ability to produce therapeutics at high level for a prolonged period of time makes this combination potentially very powerful. This collaboration follows our strategy of bringing gtGTU to the gene therapy market through strong partnerships.”